文献速递药物相互作用特殊人群用药

肝脏CYP3A4发育功能对儿科PBPK/PD建模中药物相互作用风险的影响:文献综述与伊伐布雷定案例研究

Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
PubMed 文献 · Clin Pharmacol Ther · 2020-12-31

该研究通过建立伊伐布雷定及其代谢物的成人至儿童PBPK/PD模型,预测与强CYP3A4抑制剂的药物相互作用,并比较两种CYP3A4肝发育函数(Salem和Upreti)的敏感性。模型在74名儿童中满意预测PK/PD,但不同发育函数导致幼儿AUC和心率变化预测差异,且对DDI敏感性预测不同,强调需谨慎考虑肝CYP3A4发育函数对儿科标签的影响。

要点

  • 儿童DDI临床评估不常见,PBPK建模可支持药物标签。
  • 伊伐布雷定PBPK/PD模型在74名儿童中满意预测PK/PD。
  • 选择CYP3A4肝发育函数影响幼儿DDI敏感性预测,需谨慎。

核心结论

  • 肝脏CYP3A4发育函数的选择影响儿科PBPK/PD模型预测的DDI风险,对标签建议有重要意义。

研究设计与样本

  • 基于伊伐布雷定及其代谢物的成人PBPK/PD模型缩放至74名0.5-18岁儿童,比较Salem和Upreti两种CYP3A4肝发育函数。

主要发现

  • 模型满意预测儿童PK/PD,但使用Salem函数时,0.5-3岁幼儿的预测母药和代谢物AUC12h及心率变化分别比Upreti函数高2倍、1.5倍和1.4倍。
  • 使用Salem函数时,0.5-1岁幼儿 predicted 伊伐布雷定和代谢物AUCDDI/AUCcontrol 比成人低2倍。
  • 使用Upreti函数时,各年龄组伊伐布雷定DDI预测相当,但代谢物AUCDDI/AUCcontrol在幼儿与成人间高1.3倍。
  • PD方面,不同年龄组和两种函数间预测的DDI差异较小。

临床怎么用

  • 在儿科PBPK建模中应仔细考虑肝CYP3A4发育函数的选择,以支持药物标签建议。

局限性

  • 由于PK和PD数据稀疏,选择合适的肝CYP3A4发育函数具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical assessment of drug-drug interactions (DDIs) in children is not a common practice in drug development. Therefore, physiologically-based pharmacokinetic (PBPK) modeling can be beneficial for informing drug labeling. Using ivabradine and its metabolite (both cytochrome P450 3A4 enzyme (CYP3A4) substrates), the objectives were (i) to scale ivabradine-metabolite adult PBPK/PD to pediatrics, (ii) to predict the DDIs with a strong CYP3A4 inhibitor, and (iii) to compare the sensitivity of children to DDIs using two CYP3A4 hepatic ontogeny functions: Salem and Upreti. A scaled parent-metabolite PBPK/PD model from adults to children satisfactorily predicted pharmacokinetics (PK) and pharmacodynamics (PD) in 74 children (0.5-18 years) regardless of CYP3A4 hepatic ontogeny function applied. However, using the Salem ontogeny, mean predicted parent and metabolite area under the concentration-time curve over 12 hours (AUC12h ) and heart rate change from baseline were 2-fold, 1.5-fold, and 1.4-fold higher in young children (0.5-3 years old) compared with Upreti ontogeny, respectively. Despite these differences, choice of appropriate hepatic CYP3A4 ontogeny was challenging due to sparse PK and PD data. Different sensitivity to ivabradine-ketoconazole DDIs was simulated in young children relative to adults depending on the choice of hepatic CYP3A4 ontogeny. Predicted ivabradine and metabolite AUCDDI /AUCcontrol were 2-fold lower in the youngest children (0.5-1 year old) compared with adults (Salem function). In contrast, the Upreti function predicted comparable ivabradine DDIs across all age groups, although predicted metabolite AUCDDI/ AUCcontrol was 1.3-fold higher between the youngest children and adults. In the case of PD, differences in predicted DDIs were minor across age groups and between both functions. Current work highlights the importance of careful consideration of hepatic CYP3A4 ontogeny function and implications on labeling recommendations in the pediatric population.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lang J, Vincent L, Chenel M, et al. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study. Clin Pharmacol Ther. 2020. PMID: 33283268. doi:10.1002/cpt.2134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。